+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Urinary Tract Infection Testing Market - Global Forecast 2026-2032- Product Image
Urinary Tract Infection Testing Market - Global Forecast 2026-2032- Product Image
Sale

Urinary Tract Infection Testing Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666357
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Urinary Tract Infection Testing Market is projected to reach USD 1.26 Billion in 2026. It is expected to continue growing at a CAGR of 4.65%, reaching USD 1.65 Billion by 2032.

Urinary tract infection testing is becoming a critical component of modern diagnostics as health systems work to improve antimicrobial stewardship, reduce recurrent infections, and accelerate treatment decisions across primary care, emergency medicine, urology, obstetrics, pediatrics, and long-term care. UTIs remain among the most common bacterial infections worldwide, with a high clinical burden among women, older adults, pregnant patients, catheterized individuals, people with diabetes, and immunocompromised populations. Traditional urinalysis and urine culture continue to provide foundational evidence for diagnosis, while rapid dipstick testing, automated urine sediment analysis, mass spectrometry-enabled organism identification, molecular assays, antimicrobial susceptibility testing, and point-of-care platforms are reshaping how clinicians confirm infection and identify resistance. The executive priority is shifting from simple detection to clinically actionable urinary tract infection testing that supports faster diagnosis, targeted antibiotic use, reduced complications, and improved patient pathways.

Transformative Shifts in the Urinary Tract Infection Testing Landscape

The urinary tract infection testing landscape is undergoing a decisive transition from centralized, culture-dependent workflows toward faster, integrated, and patient-centric diagnostic models. Rising concern over antimicrobial resistance is increasing demand for tests that can distinguish bacterial infection from colonization, identify pathogens earlier, and support susceptibility-informed therapy. Clinical laboratories are adopting automation to improve throughput, standardize interpretation, and reduce turnaround time, while healthcare providers are expanding point-of-care urine testing in outpatient, urgent care, long-term care, and remote-care settings. Digital connectivity is also transforming reporting workflows by linking diagnostic results with electronic health records, clinical decision support, and antimicrobial stewardship programs. At the same time, regulatory expectations for analytical validity, clinical performance, quality management, and responsible test interpretation are strengthening, particularly for molecular urinary tract infection diagnostics. These shifts are positioning UTI testing as a strategic diagnostic category aligned with precision medicine, infection control, and value-based care.

Cumulative Impact of Artificial Intelligence on UTI Testing

Artificial intelligence is increasingly influencing urinary tract infection testing by improving image-based urine sediment analysis, automating microscopic review, supporting culture interpretation, and helping clinicians identify patients at risk of complicated or recurrent UTI. AI-enabled platforms can assist laboratories in triaging negative samples, flagging abnormal findings, reducing manual workload, and improving consistency in high-volume testing environments. In clinical care, machine learning models can combine urinalysis parameters, patient demographics, prior microbiology results, comorbidities, catheter status, pregnancy status, and prescribing history to support diagnostic confidence and antibiotic selection. The most meaningful impact is expected where AI is embedded into validated workflows rather than used as a standalone decision-maker. Data quality, demographic representativeness, cybersecurity, explainability, auditability, and clinical governance remain essential to safe adoption. When implemented responsibly, AI can help reduce unnecessary antibiotic prescribing, shorten time to targeted therapy, and enhance surveillance of resistance patterns in urinary tract pathogens.

Key Regional Insights Across Global UTI Testing Adoption

In Asia-Pacific, urinary tract infection testing demand is shaped by dense urban populations, expanding diagnostic infrastructure, high outpatient volumes, aging demographics, and growing attention to antimicrobial resistance surveillance in countries such as China, India, Japan, South Korea, and Australia. The region is seeing broader use of automated urinalysis, culture confirmation, and rapid testing as public and private providers work to improve access and laboratory efficiency. Europe benefits from established microbiology standards, stewardship-focused prescribing guidance, in vitro diagnostic oversight, and a strong emphasis on evidence-based use of urinalysis, urine culture, and susceptibility testing across primary and secondary care. North America is characterized by mature clinical laboratory networks, strong uptake of electronic health records, antimicrobial stewardship requirements, and increasing interest in molecular and point-of-care UTI diagnostics, particularly for recurrent, catheter-associated, and complicated infections. Latin America is advancing diagnostic access through hospital-based laboratories, public health programs, and private diagnostic networks, although variability in reimbursement, laboratory capacity, and rural access continues to influence testing pathways. Africa presents a dual reality: major unmet need for accessible UTI diagnostics alongside growing laboratory strengthening initiatives, where affordable point-of-care testing, antimicrobial resistance monitoring, and specimen referral systems are increasingly important for improving patient outcomes. The Middle East is investing in hospital modernization, digital healthcare, and advanced diagnostics, with UTI testing needs closely tied to diabetes prevalence, catheter-associated infections, expanding tertiary care services, and infection prevention priorities.

Key Group Insights for UTI Testing Priorities

NATO member countries, many of which overlap with advanced healthcare economies, place growing emphasis on resilient healthcare infrastructure, military and civilian infection surveillance, and standardized diagnostic readiness, reinforcing the importance of reliable urinary tract infection testing across routine, deployed, and high-acuity care settings. G7 countries generally show mature reimbursement structures, well-developed microbiology infrastructure, high digital health penetration, and strong adoption of automation, quality systems, and clinical decision support for UTI diagnosis. BRICS countries represent diverse but high-impact diagnostic environments, combining large patient populations, rising chronic disease burden, expanding laboratory networks, and increasing emphasis on affordable rapid testing that can support antibiotic optimization. The European Union is a leading policy environment for antimicrobial stewardship, in vitro diagnostic regulation, laboratory quality assurance, and cross-border resistance monitoring, creating strong demand for validated, clinically interpretable UTI testing methods. ASEAN countries are strengthening urinary tract infection testing capacity through expanding primary care access, hospital laboratory modernization, and regional efforts to address antimicrobial resistance, although diagnostic standardization and rural access remain uneven. GCC health systems are prioritizing advanced hospital diagnostics, digital health integration, and infection control, making rapid UTI testing and susceptibility-informed treatment relevant to tertiary care, outpatient settings, and chronic disease management.

Key Country Insights in Urinary Tract Infection Testing

China is rapidly expanding automated laboratory diagnostics and hospital-based molecular capabilities, driven by large patient volumes, urban hospital modernization, and national concern around antimicrobial resistance. The United States has a highly developed urinary tract infection testing ecosystem supported by extensive outpatient testing, hospital microbiology capacity, antimicrobial stewardship programs, electronic health record integration, and growing use of molecular diagnostics for complex cases. Japan has advanced laboratory automation, an aging population, and strong clinical emphasis on managing complicated infections in hospital and long-term care settings. India faces high UTI burden and significant variation in access to culture and susceptibility testing, making affordable rapid diagnostics, specimen quality improvement, and stewardship education especially important. Germany, the United Kingdom, France, Italy, and Spain demonstrate mature European testing environments where urinalysis, urine culture, susceptibility testing, and prescribing guidance are closely linked to stewardship objectives, laboratory accreditation, and quality standards. Australia combines robust microbiology infrastructure with stewardship-focused guidelines, while remote and regional access remains an important consideration for urine testing pathways. South Korea is characterized by advanced hospital laboratories, digital healthcare adoption, and focused management of complicated infections among older and hospitalized patients. Canada emphasizes evidence-based testing, stewardship, and equitable access across provincial healthcare systems, with particular focus on appropriate urine culture use and resistance monitoring. Russia maintains substantial hospital-based diagnostic capacity, with ongoing need for resistance surveillance and standardized testing access across a large geography. Brazil and Mexico are strengthening diagnostic access through public and private laboratory networks, while antibiotic resistance, variability in testing availability, and high primary care demand shape clinical practice.

Actionable Recommendations for UTI Testing Industry Leaders

Industry leaders should prioritize clinically validated urinary tract infection testing solutions that shorten time to actionable results while supporting antimicrobial stewardship. Investments should focus on rapid pathogen detection, susceptibility-informed workflows, automated urinalysis, laboratory information system connectivity, and decision support that helps clinicians avoid overtreatment of asymptomatic bacteriuria. Developers should generate strong clinical evidence across diverse patient groups, including older adults, pregnant patients, pediatric patients, catheterized patients, recurrent UTI populations, and regions with high antimicrobial resistance. Laboratories and providers should integrate testing algorithms that combine symptom assessment, urinalysis, culture confirmation, and resistance profiling based on clinical risk. Point-of-care solutions should be designed for usability, quality control, operator training, and result traceability, especially in primary care, urgent care, long-term care, and low-resource settings. Leaders should also build partnerships with healthcare systems to support training, diagnostic stewardship, data interoperability, and resistance surveillance without increasing inappropriate test utilization.

Research Methodology for Evidence-Based UTI Testing Insights

This executive summary is developed using a secondary research approach grounded in verified public health, clinical, regulatory, and scientific sources. The methodology includes review of peer-reviewed literature on urinary tract infection diagnosis, antimicrobial resistance, urinalysis, urine culture, rapid testing, molecular diagnostics, antimicrobial susceptibility testing, and point-of-care testing. It also considers guidance and surveillance perspectives from recognized health authorities, infection control bodies, laboratory medicine organizations, antimicrobial stewardship frameworks, and in vitro diagnostic regulatory references. Regional and country insights are synthesized from documented healthcare infrastructure trends, diagnostic access patterns, clinical practice environments, disease burden considerations, and regulatory factors. The analysis deliberately excludes market sizing, market estimation, market share, and forecasting, focusing instead on evidence-backed industry dynamics, clinical needs, technology adoption, and strategic implications. All insights are interpreted through the lens of diagnostic utility, patient outcomes, laboratory workflow, antimicrobial stewardship, and healthcare system readiness.

Conclusion on the Future of Urinary Tract Infection Testing

Urinary tract infection testing is evolving from routine urine screening into a strategically important diagnostic field that supports faster clinical decisions, improved antibiotic stewardship, and better management of complicated and recurrent infections. Automation, molecular diagnostics, point-of-care platforms, antimicrobial susceptibility testing, and artificial intelligence are improving the speed and consistency of UTI diagnosis, but their value depends on clinical validation, responsible interpretation, and integration with care pathways. Regional differences in laboratory capacity, reimbursement, stewardship maturity, regulatory readiness, and healthcare access will continue to shape adoption priorities. Organizations that align testing innovation with evidence-based clinical guidelines, interoperability, affordability, quality assurance, and resistance surveillance will be best positioned to meet rising diagnostic expectations while supporting safer, more targeted treatment for patients with suspected urinary tract infection.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Urinary Tract Infection Testing Market, by Test Type
7.1. Introduction
7.2. Automated Urinalysis
7.2.1. Automated Microscopy
7.2.2. Digital Imaging
7.2.3. Flow Cytometry
7.3. Culture Test
7.4. Molecular Test
7.4.1. Isothermal Amplification
7.4.2. Next Generation Sequencing
7.4.3. Pcr Assay
7.5. Rapid Test
7.5.1. Dipstick Test
7.5.2. Microscopy
8. Urinary Tract Infection Testing Market, by Technology
8.1. Introduction
8.2. Automated Systems
8.2.1. Fully Automated
8.2.2. Semi Automated
8.3. Culture Based
8.4. Immunoassays
8.4.1. Chemiluminescent Immunoassay
8.4.2. Elisa
8.4.3. Lateral Flow Assay
8.5. Molecular Diagnostics
8.5.1. Isothermal
8.5.2. Next Generation Sequencing
8.5.3. Pcr
9. Urinary Tract Infection Testing Market, by Sample Type
9.1. Introduction
9.2. Catheterized
9.3. Midstream Clean Catch
9.4. Suprapubic Aspiration
10. Urinary Tract Infection Testing Market, by Pathogen Type
10.1. Introduction
10.2. Bacterial UTI
10.3. Fungal UTI
10.4. Viral UTI
11. Urinary Tract Infection Testing Market, by Infection Type
11.1. Introduction
11.2. Lower Urinary Tract Infection
11.3. Upper Urinary Tract Infection
11.4. Complicated UTI
11.5. Uncomplicated UTI
12. Urinary Tract Infection Testing Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Diagnostic Laboratories
12.4. Home Care
12.5. Hospitals
13. Urinary Tract Infection Testing Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Urinary Tract Infection Testing Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Urinary Tract Infection Testing Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. 77 Elektronika Kft.
17.2. Abbott Laboratories
17.3. Accelerate Diagnostics, Inc.
17.4. Acon Laboratories, Inc.
17.5. Arkray, Inc.
17.6. Becton, Dickinson and Company
17.7. Bio-Rad Laboratories, Inc.
17.8. Biocare Medical, LLC
17.9. bioMérieux SA
17.10. Cardinal Health, Inc.
17.11. Danaher Corporation
17.12. Dirui Industrial Co., Ltd.
17.13. EKF Diagnostics Holdings plc
17.14. F. Hoffmann-La Roche Ltd
17.15. Hologic, Inc.
17.16. Human Diagnostics Worldwide
17.17. Macherey-Nagel GmbH & Co. KG
17.18. Meridian Bioscience, Inc.
17.19. Mindray Medical International Limited
17.20. Nanosphere Health Sciences LLC
17.21. Nova Biomedical Corporation
17.22. QIAGEN N.V.
17.23. Randox Laboratories Ltd.
17.24. Sekisui Diagnostics, LLC
17.25. Siemens Healthineers AG
17.26. Sysmex Corporation
17.27. Thermo Fisher Scientific Inc.
17.28. Trivitron Healthcare
List of Figures
FIGURE 1. GLOBAL URINARY TRACT INFECTION TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL URINARY TRACT INFECTION TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL URINARY TRACT INFECTION TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL URINARY TRACT INFECTION TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL URINARY TRACT INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL URINARY TRACT INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL URINARY TRACT INFECTION TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL AUTOMATED URINALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL AUTOMATED URINALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL AUTOMATED URINALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL AUTOMATED MICROSCOPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL AUTOMATED MICROSCOPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL AUTOMATED MICROSCOPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL DIGITAL IMAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL DIGITAL IMAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL DIGITAL IMAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CULTURE TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CULTURE TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CULTURE TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MOLECULAR TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL MOLECULAR TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL MOLECULAR TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PCR ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PCR ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PCR ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RAPID TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL RAPID TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL RAPID TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL DIPSTICK TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL DIPSTICK TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL DIPSTICK TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MICROSCOPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MICROSCOPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MICROSCOPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL AUTOMATED SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL FULLY AUTOMATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL FULLY AUTOMATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL FULLY AUTOMATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SEMI AUTOMATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SEMI AUTOMATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SEMI AUTOMATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CULTURE BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CULTURE BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CULTURE BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ELISA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ELISA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ISOTHERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ISOTHERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ISOTHERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CATHETERIZED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CATHETERIZED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CATHETERIZED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL MIDSTREAM CLEAN CATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL MIDSTREAM CLEAN CATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL MIDSTREAM CLEAN CATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL SUPRAPUBIC ASPIRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL SUPRAPUBIC ASPIRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SUPRAPUBIC ASPIRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL BACTERIAL UTI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BACTERIAL UTI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL BACTERIAL UTI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL FUNGAL UTI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL FUNGAL UTI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL FUNGAL UTI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL VIRAL UTI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL VIRAL UTI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL VIRAL UTI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL LOWER URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL LOWER URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL LOWER URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL UPPER URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL UPPER URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL UPPER URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL COMPLICATED UTI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL COMPLICATED UTI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL COMPLICATED UTI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 139. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 140. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 141. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 142. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 143. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 144. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 145. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 146. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 147. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 148. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 149. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 172. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 173. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 177. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 178. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 179. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 180. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 181. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 182. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 183. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 184. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 185. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 186. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 187. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 188. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 198. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 199. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 200. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 202. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 205. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 206. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 207. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 208. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 209. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 210. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 211. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 212. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 213. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 214. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 215. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 216. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 217. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 218. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 219. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 220. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 221. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 222. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 223. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 224. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 225. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 226. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 227. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 228. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 230. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 231. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 232. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 233. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 234. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 235. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 236. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 237. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 238. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 239. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 240. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 241. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 256. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 257. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 258. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 259. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 260. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 261. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 262. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 263. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 264. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 265. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 266. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 267. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 269. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 270. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 271. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 272. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 273. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 274. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 275. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 276. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 277. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 278. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 279. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 280. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 281. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 282. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 284. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 285. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 286. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 287. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 288. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 289. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 290. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 291. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 292. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 293. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 294. CHINA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 300. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 302. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 303. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 304. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 305. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 306. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 307. UNITED STATES URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 310. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 311. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 312. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 313. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 314. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 315. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 316. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 317. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 318. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 319. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 320. JAPAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 322. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 323. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 324. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 325. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2017-2032 (USD MILLION)
TABLE 326. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 327. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2017-2032 (USD MILLION)
TABLE 328. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 329. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 330. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 331. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 332. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 333. INDIA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. GERMANY URINARY TRACT INFECTION TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 335. GERMANY URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 336. GERMANY URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2017-2032 (USD MILLION)
TABLE 337.

Companies Mentioned

  • 77 Elektronika Kft.
  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Acon Laboratories, Inc.
  • Arkray, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocare Medical, LLC
  • bioMérieux SA
  • Cardinal Health, Inc.
  • Danaher Corporation
  • Dirui Industrial Co., Ltd.
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Human Diagnostics Worldwide
  • Macherey-Nagel GmbH & Co. KG
  • Meridian Bioscience, Inc.
  • Mindray Medical International Limited
  • Nanosphere Health Sciences LLC
  • Nova Biomedical Corporation
  • QIAGEN N.V.
  • Randox Laboratories Ltd.
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare

Table Information

Report AttributeDetails
No. of Pages191
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.26 Billion
Forecasted Market Value ( USD ) by 2032 $ 1.65 Billion
Compound Annual Growth Rate4.6%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Urinary Tract Infection Market - Global Forecast 2026-2032 - Product Image

Urinary Tract Infection Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Urinary Tract Infection Testing Devices Market Report 2026 - Product Image

Urinary Tract Infection Testing Devices Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Uncomplicated Urinary Tract Infection Market Report 2026 - Product Image

Uncomplicated Urinary Tract Infection Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Urinary Tract Infection Testing Market - Forecast from 2026 to 2031 - Product Image

Urinary Tract Infection Testing Market - Forecast from 2026 to 2031

  • Report
  • 143 Pages
  • Global
From
Urinary Tract Infection Testing Market - Global Strategic Business Report - Product Image

Urinary Tract Infection Testing Market - Global Strategic Business Report

  • Report
  • 300 Pages
  • Global
From

About the Urinary Tract Infection Testing Market

The Urinary Tract Infection (UTI) Testing market is a subset of the Urology and Nephrology industry. It is focused on the diagnosis and treatment of UTIs, which are caused by bacteria entering the urinary tract. UTI testing is used to identify the presence of bacteria in the urine, as well as to determine the type of bacteria present. Tests may include urine cultures, urine microscopy, and urine antigen tests. Treatment typically involves antibiotics, and in some cases, surgery. The UTI Testing market is driven by the increasing prevalence of UTIs, as well as the need for accurate diagnosis and treatment. The market is expected to grow in the coming years, as new technologies and treatments are developed. Some companies in the UTI Testing market include Siemens Healthineers, Abbott Laboratories, Becton Dickinson, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.